Figure 3

SCFD2 is a potential prognostic factor of ER-positive breast cancer patients and combinations of PSPC1/PSF/SCFD2 IRs are potently associated with poor prognosis in ER-positive breast cancer patients. (A–C) Representative images of ER-breast tumor sections with strong (A) and weak (B) SCFD2 IR and benign breast duct (C). Scale bar, 50 μm. (D,E) Kaplan–Meier plots for disease-free (D) and overall (E) survivals of ER-positive breast cancer patients with weak and strong SCFD2 IR (n = 69 and 45, respectively). (F,G) Disease relapse rates (F) and death rates (G) among ER-positive breast cancer patients categorized by PSPC1/PSF/SCFD2 IR status. (H,I) Kaplan–Meier plots for disease-free (H) and overall (I) survivals of ER-positive breast cancer patients categorized by PSPC1/PSF/SCFD2 IR scores. Score 0: weak IR for all three proteins, score 1: strong IR for any single protein of PSPC1/PSF/SCFD2, score 2: strong IR for any two proteins of PSPC1/PSF/SCFD2, and score 3: strong IR for all three proteins. For multiple comparisons, significance is assessed at P < 0.05 following Bonferroni correction.